Global Bispecific Antibody Market Opportunity & Clinical Trials Insight 2023 Report Highlights:
- Yearly & Quarterly Sales Insight (2018 till Q1’2023)
- Global & Regional Sales Insights
- Global Market Forecast Till 2028
- Approved Bispecific Antibodies: 9
- Insight On Bispecific Antibodies In Clinical Trials: > 700 Bispecific Antibodies
- Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
- Fast Track Approval, Orphan Designation & Priority Status Insights
- Approved Bispecific Antibodies Pricing & Dosage Analysis
- Competitive Landscape: Top 50 Companies Developing Bispecific Antibodies
Download Report:
Bispecific antibodies market is one of the fastest growing domains of the global pharmaceutical market, and many driving factors are continuously fanning its growth. The global market reached an all-time high in 2022, and closed at US$ 5.7 Billion. The US market generated a majority of this revenue thanks to the increasing uptake of these drugs, which has been rising every quarter. For several years now, Hemlibra has been the highest selling bispecific antibody globally, accounting for almost 75% of the total revenue generated in the year 2022.
Many favorable market factors have been aiding the growth of the global bispecific antibody market such as increased spending and investment on the development of novel drug candidates, as well as the increasing spending on healthcare by the public. Moreover, many central governments have launched schemes and programs to reimburse drug manufacturers which resulted in increased prescriptions of bispecific drugs by doctors, resulting in a higher uptake. Such factors are anticipated to continue in the foreseeable future, which will help the bispecific antibodies market grow untapped in no time.</P
Contact:
Neeraj Chawla
Kuick Research
Research Head